{"id":29144,"date":"2012-05-12T16:51:44","date_gmt":"2012-05-12T20:51:44","guid":{"rendered":"http:\/\/countingpips.com\/fx\/?p=29144"},"modified":"2012-05-12T16:51:44","modified_gmt":"2012-05-12T20:51:44","slug":"intermune-shares-fall-after-delay-in-trial-of-esbriet","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/fx\/2012\/05\/12\/intermune-shares-fall-after-delay-in-trial-of-esbriet\/","title":{"rendered":"InterMune Shares Fall After Delay in Trial of Esbriet"},"content":{"rendered":"<p><div id=\"grabDiv1767162\"><object id=\"GrabPlayer1767162\" width=\"542\" height=\"304\" type=\"application\/x-shockwave-flash\" align=\"middle\" data=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v9364fd9613f5f19a7af1f0ab0c2fc8f66395ce26&#038;tgt=grabnetworks\"><param name=\"quality\" value=\"high\"\/><param name=\"allowScriptAccess\" value=\"always\"\/><param name=\"allowFullScreen\" value=\"true\"\/><param name=\"menu\" value=\"false\"\/><param name=\"wmode\" value=\"transparent\"\/><param name=\"movie\" value=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v9364fd9613f5f19a7af1f0ab0c2fc8f66395ce26&#038;tgt=grabnetworks\"\/><\/object><\/p>\n<div id=\"overlay-adzone\" style=\"overflow:hidden; position:relative\"><\/div>\n<\/div>\n<p>InterMune (NASDAQ:ITMN) shares fell 13% to $13.24 after news broke that a significant trial for its drug Esbriet was postponed.Last week, the company announced it didn&#8217;t expect enrollment for the Phase III clinical trial to be finish by the end of the year, when the company predicted enrollment to be finish by the second quarter.InterMune (NASDAQ:ITMN) has potential upside of 119.3% based on a current price of $12.7 and an average consensus analyst price target of $27.85.<\/p>\n<p><img src='http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/05\/12\/1_0srjchn5_thumb.jpg' \/><\/p>\n<p><!--post_img[http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/05\/12\/1_0srjchn5_preview.jpg]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InterMune (NASDAQ:ITMN) shares fell 13% to $13.24 after news broke that a significant trial for its drug Esbriet was postponed.Last week, the company announced it didn&#8217;t expect enrollment for the Phase III clinical trial to be finish by the end of the year, when the company predicted enrollment to be finish by the second quarter.InterMune &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/fx\/2012\/05\/12\/intermune-shares-fall-after-delay-in-trial-of-esbriet\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InterMune Shares Fall After Delay in Trial of Esbriet&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-29144","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/comments?post=29144"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/media?parent=29144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/categories?post=29144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/tags?post=29144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}